PTD-DBM vs Nonapeptide-1
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Also: Melanostatine 5, Melanostatine-5
Nonapeptide-1, sold as Melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-MSH, the hormone that tells pigment cells to make melanin. It goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. It is a cosmetic ingredient, not an FDA-approved drug, and there is no independent peer-reviewed clinical trial of it on its own.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to Nonapeptide-1 (Limited Research).
Detailed Comparison
| Attribute | PTD-DBM | Nonapeptide-1 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. | When skin is hit by UV, it releases alpha-MSH, which binds the MC1R receptor on melanocytes and switches on tyrosinase, the enzyme that makes melanin. Nonapeptide-1 is designed to sit in that receptor without switching it on, a competitive antagonist, so less of the tanning and pigment signal gets through. In cell studies it binds MC1R with high affinity and blocks alpha-MSH-driven melanosome dispersion at nanomolar levels, and it lowered tyrosinase and related pigment genes in human melanocytes. It is essentially the opposite of melanotan I and afamelanotide, which activate the same receptor to darken skin. The big unknown, as with most cosmetic peptides, is how much reaches melanocytes through intact skin. |
| Common Dosing | Supplied as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water approximates the ~6 mg/mL used in the mouse study Once daily to the scalp in most community-reported routines | Low percentage in a brightening serum Once or twice daily |
| Administration | Topical (applied to skin) in published research; usually co-applied with valproic acid | Topical (serums, creams) |
| Typical Duration | Applied over several weeks in animal studies | Brightening claims are usually judged over 8 to 12 weeks; ongoing use |
| Best Time to Take | Not established (topical in animal studies) | Morning (under sunscreen) and/or evening |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a topical liquid of about 6 mg/mL PTD-DBM plus about 72 mg/mL valproic acid outperformed roughly 2% minoxidil in that model (the study reported these as solution concentrations: 2 mM, 500 mM, and 100 mM). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. | The evidence is thin and mostly commercial. Receptor binding and anti-pigment effects come from cell work and supplier data sheets. In a 2022 paper in Postepy Dermatologii i Alergologii (Chen and colleagues), nonapeptide-1 was used as a reference MC1R blocker in UVA-exposed human melanocytes and keratinocytes, where it reduced pigment pathway activity, but the study's focus was tea polyphenols, not the peptide. Ingredient databases describe the human data as small and manufacturer-generated. You will see claims online of a 12-week, 40-person trial where a cream with this peptide matched 4 percent hydroquinone for melasma, but we could not find a published, citable version, and even then it was a multi-ingredient cream. Fair summary: a well-designed molecule with a clear mechanism in cells, and very little real-world proof. Sunscreen still does more for dark spots than any single brightening peptide. |
Frequently Asked Questions: PTD-DBM vs Nonapeptide-1
What is the difference between PTD-DBM and Nonapeptide-1?
PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. Nonapeptide-1 is a skin & hair peptide that nonapeptide-1, sold as melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-msh, the hormone that tells pigment cells to make melanin. it goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. it is a cosmetic ingredient, not an fda-approved drug, and there is no independent peer-reviewed clinical trial of it on its own. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PTD-DBM or Nonapeptide-1?
Neither is universally "better" - the choice depends on your specific goals. PTD-DBM is typically used for skin & hair purposes, while Nonapeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PTD-DBM and Nonapeptide-1 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PTD-DBM and Nonapeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.